Navigation Links
Oligonucleotide Delivery: Biology, Engineering and Development Conference

Oligonucleotide technologies, such as siRNA, tap into endogenous, highly conserved and specific catalytic mechanisms to efficiently regulate gene expression. As such, they have the potential to enable the development of novel therapeutic options for disease targets previously considered un-druggable by conventional small molecule and biologics means. However, despite the promise, clinical development has been hindered by the challenges encountered by identifying and developing safe and efficacious delivery formulations.

Since its discovery in 1998, RNA silencing has attracted much attention, with over 50,000 peer-reviewed publications, multiple national and international conferences, and significant investment in the biotech and large pharma with the goal of developing new siRNA-based therapies. Despite the interest and investment this has proven to be more difficult that first envisioned. It is widely recognized that there are gaps in our basic understanding on how to best harness this technology for therapeutic use.

The major topics to be discussed are:

Liposomes, nanosomes, polymeric and nano-particulate delivery vehicles
RNA chemical modifications and conjugates to enable delivery
Protein transduction domain as delivery platforms
Mechanisms of cellular uptake and endosomal escape
Biophysical characterization methods
siRNA delivery vehicle toxicology
Local and systemic siRNA delivery case studies

Confirmed Speakers
Achim Aigner, Philipps-University Marburg, Germany
Saghir Akhtar, Kuwait University, Kuwait
Eben Alsberg, Case Western Reserve University, USA
Dan Anderson, MIT, USA
Tomohiro Asai, University of Shizuoka, Japan
Himanshu Brahmbhatt, EnGeneIC Ltd, Australia
Bob Brown, Dicerna, USA
Kenneth Clark, GlaxoSmithKline, UK
Pieter Cullis, University of British Columbia, Canada
Mark E. Davis, California Institute of Technology, USA
Derek M. Dykxhoorm, University of Miami Miller School of Medicine, USA
Xavier de Mollerat Du Jeu, Life Technologies, USA
Omid Farokhzad, Harvard Medical School, USA
Elena Feinstein, Quark Pharma, Israel / USA
Mauro Ferrari, The Methodist Hospital Research Institute, USA
Mercedes Gonzlez-Juarrero, Colorado State University, USA
Tatsuhiro Ishida, The University of Tokushima, Japan
Rudy Juliano, University of North Carolina Chapel Hill, USA
Jan Kamps, University of Groningen, The Netherlands
Kazunori Kataoka, University of Tokyo, Japan
Jrgen Kjems, rhus University, Denmark
Troels Koch, Santaris Pharma A/S, Denmark / USA
lo Langel, Stockholm University, Sweden
Gabriel Lpez-Berestein, The University of Texas MD Anderson Cancer Center, USA
Zheng-Rong Lu, Case Western Reserve University, USA
Jennifer MacDiarmid, EnGeneIC Ltd, Australia
Ram I. Mahato, University of Tennessee Health Science Center, USA
Muthiah Manoharan, Alnylam Pharmaceuticals, USA
Nigel A.J. McMillan, Diamantina Institute, University of Queensland, Australia X
in Ming, University of North Carolina Chapel Hill, USA
Tamara Minko, Rutgers University, USA
Andrs Montefeltro, nLife Therapeutics, Spain
Sterghios Moschos, University of Westminster, UK
Deborah Palliser, Albert Einstein School of Medicine, USA
Dan Peer, Tel Aviv University, Israel
Jean Phillipe Pellois, Texas A&M University, USA
Blake Peterson, The University of Kansas, USA
Tariq M. Rana, Sanford-Burnham Medical Research Institute, USA
Steven L. Regen, Lehigh University, USA
John Rossi, City of Hope, Duarte, USA
Dmitry Samarsky, RiboBio, China
Ansgar Santel, Silence Therapeutics AG, Germany
Alan D. Schreiber, ZaBeCor Pharmaceuticals, Inc., USA
Sabine Schreidler, Sanofi-Aventis, Germany
Georg Sczakiel, University of Lbeck, Germany
Peter H. Seeberger, Max Planck Institute of Colloids and Interfaces, Berlin, Germany
Rita Serda, Methodist Hospital Research Institute, USA
Mouldy Sioud, Norwegian Radium Hospital, Norway
Anil Sood, MD Anderson Cancer Center, USA
Janos Szebeni, Semmelweis University, Budapest, Hungary
C. Shad Thaxton, Northwestern University, USA
Ernst Wagner, Ludwig-Maximilians-Universitat, Munchen, Germany
Roberto Weinmann, Sylentis, Spain
Johannes Winkler, University of Vienna, Austria
You-Yeon Won, Purdue University, USA
Matthew Wood, Oxford University, UK
Miqin Zhang, University of Washington, USA


Contact: Kevin Korpics
Engineering Conferences International

Related biology news :

1. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
2. Melting glaciers, enough sand to bury London, and ancient ecosystem engineering
3. Innovative cell printing technologies hold promise for tissue engineering R&D
4. 5th Annual Advances in Biomolecular Engineering Symposium
5. Medical device, health professionals attend first national conference on value-driven engineering
6. NSF report detailing growth in graduate enrollment in science & engineering in the past decade
7. Investigation of American Oriental Bioengineering, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
8. Artificial womb unlocks secrets of early embryo development
9. REST is crucial for the timing of brain development
10. Embryonic development protein active in cancer growth
11. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
Post Your Comments:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology: